Swedish Orphan Biovitrum AB (publ) (OTCMKTS:SWTUY) is a Stockholm-based biopharmaceutical company specializing in the development, manufacturing and commercialization of therapies for rare diseases and specialty care. The company’s portfolio spans treatments in hematology, immunology and metabolic disorders. Its research and development efforts focus on addressing unmet medical needs by advancing both proprietary and in-licensed drug candidates through clinical and regulatory pathways.
The company’s flagship offerings include clotting factor products for hemophilia, enzyme replacement therapies for lysosomal storage disorders and targeted immunomodulators for inflammatory conditions. Swedish Orphan Biovitrum maintains integrated manufacturing capabilities in Europe, ensuring quality control from early-stage development through commercial scale-up. In addition to its own pipeline, the firm has established partnerships with other biotech and pharmaceutical companies to expand access to innovative treatments worldwide.
Founded in 2001 following the merger of Swedish Orphan International and Biovitrum, the company has grown its presence across Europe, North America and selected markets in Asia Pacific and the Middle East. Its global commercial infrastructure supports direct operations and distribution networks in key regions, while regulatory affiliates coordinate submissions and post-marketing activities. This geographic footprint enables broad patient access to specialized therapies in countries with established rare-disease frameworks.
Under the leadership of President and Chief Executive Officer Geoffrey McDonough, Swedish Orphan Biovitrum continues to invest in late-stage clinical development and strategic in-licensing to fuel long-term growth. The company’s management team combines scientific expertise with commercial experience, guiding its mission to deliver high-impact treatments to underserved patient populations. Ongoing priorities include pipeline advancement, manufacturing expansion and fostering collaborations that enhance therapeutic innovation.
AI Generated. May Contain Errors.
